CD274 and neoplasm: An Fc-competent PD-L1*TIGIT bispecific antibody promoted greater T cell expansion and tumor cell killing than benchmark antibodies and antibody combinations in an Fc-dependent manner, indicating that the TIGIT-mediated beneficial properties may be related to both T cell and NK cell activation [45].